Founded in 2010, SHINE is a nuclear technology company working to become the world's leading provider of radioisotopes for nuclear medicine. The SHINE system uses a patented, proprietary manufacturing process that offers major advantages over existing and proposed production technologies. It does not require a nuclear reactor, is better for the environment, generates less waste and is compatible with the nation's existing supply chain for Mo-99. In 2014, SHINE announced the execution of Mo-99 supply agreements with GE Healthcare and Lantheus Medical Imaging. In 2015, with the help of Argonne National Laboratory, GE Healthcare demonstrated that SHINE Mo-99 can act as a drop-in replacement for reactor-based Mo-99. In 2016, SHINE received regulatory approval from the Nuclear Regulatory Commission to construct its production facility. The company began construction of the facility in the spring of 2019 and strong progress on it continues. SHINE created SHINE Therapeutics in 2019 to enhance the company's ability to fill critical needs in the rapidly growing therapeutic isotope market. The division is focused on the commercialization of Lu-177, a therapeutic isotope that is combined with a disease-specific target molecule to treat cancer.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 09/03/20 | $80,000,000 | Series C |
Fidelity Management & Research Company | undisclosed |
